Next Article in Journal
Evaluation of Antifungal Activity of Naja pallida and Naja mossambica Venoms against Three Candida Species
Next Article in Special Issue
Comparison between Conventional Blind Injections and Ultrasound-Guided Injections of Botulinum Toxin Type A into the Masseter: A Clinical Trial
Previous Article in Journal
Determination of Aflatoxin M1 in Raw Milk from Different Provinces of Ecuador
Previous Article in Special Issue
Rectus Femoris Characteristics in Post Stroke Spasticity: Clinical Implications from Ultrasonographic Evaluation
Open AccessPerspective

Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature

Department of Neurology, University Hospital of Düsseldorf, Moorenstrasse 5, D-40225 Düsseldorf, Germany
*
Author to whom correspondence should be addressed.
Toxins 2020, 12(8), 499; https://doi.org/10.3390/toxins12080499
Received: 30 June 2020 / Revised: 29 July 2020 / Accepted: 30 July 2020 / Published: 4 August 2020
(This article belongs to the Special Issue Botulinum Neurotoxin Injection)
The three different botulinum toxin type A (BoNT/A) preparations being licensed in Europe and the U.S. differ in protein content, which seems to be a major factor influencing the antigenicity of BoNT/A. In the present study, several arguments out of our research pool were collected to demonstrate that the clinical response and antigenicity were different for the three BoNT/A preparations: some results of (1) a cross-sectional study on clinical outcome and antibody formation of 212 patients with cervical dystonia (CD) being treated between 2 and 22 years; (2) another cross-sectional study on the clinical aspects and neutralizing antibody (NAB) induction of 63 patients having developed partial secondary treatment under abobotulinum (aboBoNT/A) onabotulinumtoxin (onaBoNT/A) who were switched to incobotulinumtoxin (incoBoNT/A) in comparison to 32 patients being exclusively treated with incoBoNT/A. These results imply that (1) the presence of NAB cannot be concluded from the course of treatment, that (2) an increase in the dose and variability of outcome with treatment duration indicates the ongoing induction of NABs over time, that (3) the higher protein load of BoNT/A goes along with a higher incidence and prevalence of NAB induction and that (4) the best response to a BoNT/A is also dependent on the protein load of the preparation. View Full-Text
Keywords: low antigenicity; incobotulinum toxin; neutralizing antibodies; secondary treatment failure; complex proteins: botulinum toxin type A; cervical dystonia low antigenicity; incobotulinum toxin; neutralizing antibodies; secondary treatment failure; complex proteins: botulinum toxin type A; cervical dystonia
Show Figures

Figure 1

MDPI and ACS Style

Samadzadeh, S.; Ürer, B.; Brauns, R.; Rosenthal, D.; Lee, J.-I.; Albrecht, P.; Hefter, H. Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature. Toxins 2020, 12, 499. https://doi.org/10.3390/toxins12080499

AMA Style

Samadzadeh S, Ürer B, Brauns R, Rosenthal D, Lee J-I, Albrecht P, Hefter H. Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature. Toxins. 2020; 12(8):499. https://doi.org/10.3390/toxins12080499

Chicago/Turabian Style

Samadzadeh, Sara; Ürer, Beyza; Brauns, Raphaela; Rosenthal, Dietmar; Lee, John-Ih; Albrecht, Philipp; Hefter, Harald. 2020. "Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature" Toxins 12, no. 8: 499. https://doi.org/10.3390/toxins12080499

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop